I agree that the cosopt will level off, but I think that hitk may have a nice real niche. Although not an exclusive, with the canadian company having problems, hitk may have enjoyed a defacto exclusivity, with others scared by those already in the field. Also the governmental contract gives hitk nearly $5 million more a quarter, when hitk sold 9 - 10 million last quarter. This means that hitk may have more to go with this drug before it levels off.

I would also note that there seems to have been no more insider selling for nearly one month. Maybe that means that they've sold as much as they could or want to, and that it makes sense to hold until the quarterly report because they know it's good. Then, SEC rules may prohibit them from selling.